Millennium Management’s BridgeBio Pharma BBIO Stock Holding History

Millennium Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-7,500	Closed	-$206K	–	5862
2024 Q4	$206K	Buy	+7,500	New	+$194K	﹤0.01%	5293
2024 Q2	–	Sell	-82,500	Closed	-$2.55M	–	5880
2024 Q1	$2.55M	Buy	82,500 +47,500	+136%	+$1.62M	﹤0.01%	3508
2023 Q4	$1.41M	Buy	+35,000	New	+$1.05M	﹤0.01%	3883
2022 Q1	–	Sell	-20,000	Closed	-$334K	–	6896
2021 Q4	$334K	Buy	+20,000	New	+$846K	﹤0.01%	5431

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Millennium Management's BBIO Position: Q2 2026 in Review

Millennium Management reduced its BridgeBio Pharma (BBIO) stake by 23% in Q2 2026, selling an estimated $10.2M and leaving 487,594 shares worth $36.3M. The position accounts for 0.01% of the portfolio, ranked #1119.

Millennium Management first reported a position in BBIO in Q2 2019 and has held it in 26 quarters since. The position peaked at $47M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Millennium Management held 487,594 shares of BridgeBio Pharma worth $36.3M as of Q2 2026.
Millennium Management sold 145,689 BridgeBio Pharma shares in Q2 2026, an estimated $10.2M.
BridgeBio Pharma made up 0.01% of Millennium Management's portfolio in Q2 2026, its #1119 holding.
Millennium Management first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 26 quarters since.
Millennium Management's BridgeBio Pharma position peaked at $47M in Q1 2026.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.